Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
Gabriel Tremblay, Patrick Daniele, Janis L. Breeze, Lingling Li, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay K. Nooka, Dan T. Vogl, Maria Gavriatopoulou, Meletios A Dimopoulos, Paul G. Richardson, Noa Biran, David S. Siegel, Philip Vlummens, Chantal Doyen, Thierry Façon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy, Luciano J. Costa, James E. Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc S. Raab, David Dingli, Sascha A. Tuchman, Laurent Frenzel, Ravi Vij, Gary J. Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri L. Parker, Robert F. Cornell, Lionel Karlin, Sylvain Choquet, Sundar Jagannath (2021). Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. , 21(1), DOI: https://doi.org/10.1186/s12885-021-08453-9.
